He is a Clinical and Translational Scientist and leads a research group that focuses on the development and delivery of definitive trials in the area of cardiovascular disease in patients with kidney failure, and the development of advanced therapeutics.
A major theme of his research group is the introduction of Cardiopulmonary Exercise Testing (CPET) into the field of cardio-nephrology, and to create advanced peptide therapeutics inspired by nature.
Dr. Lim has a special interest in bioinnovation, healthcare entrepreneurship, and translational strategies for taking biological discoveries into early phase exploratory trials.
Our primary R&D platform focuses on therapeutic strategies for targeting cardiovascular disease in kidney failure, a current global health crisis.
One of the major platform technologies in our clinical research lab focuses on the use of state-of-the-art Cardiopulmonary Exercise Testing (CPET) technology, a robust and powerful technology that can accurately and reproducibly assess cardiovascular functional capacity.
Our wet lab specializes in translational research that focuses on the discovery and development of peptide therapeutics for cardiac disorders in kidney failure and beyond. We lead several exciting translational research studies using multidisciplinary approaches in cell and molecular biology, bioengineering and human tissue research.
- Cardiorenal Syndrome
- Chronic Kidney Disease (CKD)
- End-Stage Kidney Disease (ESKD)
- Disaster Medicine/Nephrology